Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25429739 | 0.84 | SMN1; SMN2 (0.43) | GAAHTTMAPTSMN1; SMN2TSHR | |
| SCHEMBL2827987 | 0.84 | GAA (0.56) | GAANPC1RAB9AHTTHSD17B10 | |
| SCHEMBL750253 | 0.81 | GAA (0.54) | GAANPC1RAB9AHTTHSD17B10 | |
| SCHEMBL8035635 | 0.81 | GAA (0.40) | GAANPC1RAB9AHTTHSD17B10 | |
| SCHEMBL4093001 | 0.79 | GABRR1 (0.39) | GAANPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL741624 | 0.79 | GAA (0.40) | GAANPC1RAB9AHTTHSD17B10 | |
| SCHEMBL7923321 | 0.78 | GAA (0.51) | GAANPC1RAB9AHTTHSD17B10 | |
| SCHEMBL28892054 | 0.77 | GAA (0.43) | GAANPC1RAB9AHTTHSD17B10 | |
| SCHEMBL1198806 | 0.75 | CYP1A2 (0.40) | GAAHSD17B10HPGDELANE | |
| SCHEMBL20092593 | 0.75 | SMN1; SMN2 (0.33) | GAASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| CN-116583501-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-112074522-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2022083703-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-112074522-A | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2020-12-11 | — | — | CN | disclosed |
| EP-3548023-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102358-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-03-17 | — | — | US | disclosed |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-03-17 | — | — | US | disclosed |
| WO-2010141696-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | LOWE DEREK B | 2009-02-19 | — | — | US | disclosed |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | LOWE DEREK B | 2009-02-19 | — | — | US | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1414809-B1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER CORP (US) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | GAA 563/4885NPC1 183/4885RAB9A 1153/4885 |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | GAA 153/4885NPC1 300/4885RAB9A 2994/4885 |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | INSR, ACACA, IAPP | GAA 153/4885NPC1 300/4885RAB9A 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.